Board appointment at Rib-X Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Rib-X Pharmaceuticals, a US development-stage antibiotics company, has appointed Peter Greenleaf to its board of directors, succeeding Tony Zook. Mr Greenleaf is senior vice-president of commercial operations, corporate development and strategy at MedImmune (AstraZeneca), and is also accountable for the corporate venture capital fund, MedImmune Ventures.